论文部分内容阅读
Sobering－Plough公司的由重组α－2b干扰素注射剂（interferonα－2b，商品名Intron）和利巴韦林胶囊（ribavirin，商品名Rebetol）组成的Rebetron联合疗法获美国FDA许可用于治疗慢性丙型肝炎和原先用α干扰素治疗后复发的病例。到目前为止，α干扰素类药物是在美国唯一获得批
Sobering-Plow’s Rebetron combination therapy consisting of a recombinant interferon alpha-2b interferon (interferon alpha-2b, trade name Intron) and ribavirin (Rebetol) is approved by the U.S. FDA for the treatment of chronic type C Hepatitis and relapse after treatment with alpha interferon. So far, alpha interferon drugs have been approved only in the United States